HI
ALNY icon

Humankind Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Humankind Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-600
Closed -$274K – 28
2025
Q3 		$274K Sell
600
-296
-33% -$121K 0.06% 124
2025
Q2 		$292K Buy
+896
New +$248K 0.07% 111
2024
Q3 		– Sell
-916
Closed -$223K – 142
2024
Q2 		$223K Sell
916
-616
-40% -$97.3K 0.06% 126
2024
Q1 		$229K Buy
1,532
+262
+21% +$43.7K 0.06% 124
2023
Q4 		$243K Buy
1,270
+128
+11% +$21.8K 0.07% 119
2023
Q3 		$202K Buy
1,142
+29
+3% +$5.53K 0.08% 111
2023
Q2 		$211K Buy
+1,113
New +$221K 0.08% 116

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Humankind Investments's ALNY Position: Q4 2025 in Review

Humankind Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 600 shares — an estimated $274K sold.

Humankind Investments first reported a position in ALNY in Q2 2023 and held it in 7 quarters. The position peaked at $292K in Q2 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Humankind Investments reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Humankind Investments sold 600 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $274K.
  • Humankind Investments first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Humankind Investments's Alnylam Pharmaceuticals position peaked at $292K in Q2 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Humankind Investments's 13F filing for Q4 2025, filed 17 Feb 2026.